Alcon (ALC) announced its intention to acquire LumiThera, Inc., a leader in light-based innovations for ophthalmology. The acquisition includes LumiThera’s PBM device for the treatment of early and intermediate dry AMD.
LumiThera offers the only PBM device that has shown significant vision improvement compared to baseline for individuals with early to intermediate dry AMD.
This device stands out as the sole option demonstrating such meaningful results. Alcon aims to expand PBM office-based treatment in approved markets. This underscores the company’s commitment to people living with retinal diseases.
Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025.
“For more than 25 years, Alcon has been a leader in vitreoretinal surgery. We are excited to expand our offerings into the clinic to help millions of people living with dry AMD gain vision,” said Sean Clark, Vice President and General Manager, Global Surgical Franchise, Alcon.
